US organisation approves new HIV anti-retroviral formulation

dimeji akinloye

June 6, 2015 1:55 PM

United States Food and Drug Administration (FDA) has approved a new anti-retroviral formulation that can be mixed with food,

Community project initiatives have been identified as important in the prevention and eradication of the Human Immunodeficiency Virus and the Acquired Immune Deficiency Syndrome (HIV/AIDS) in Nigeria.

United States Food and Drug Administration (FDA) has approved a new anti-retroviral formulation that can be mixed with food, which will make t easier for children living with HIV to take their life-saving medicines.

This is contained in a joint statement issued on Saturday, June 6, by the United Nations (UN) Programme on HIV/AID (UNAIDS) and the UN Children’s Fund (UNICEF).

It quoted the UNAIDS Executive Director, Michel Sidibe, as saying that treatment innovations such as the one that replaces unpleasant and bad-tasting medicines were a real breakthrough.

Sidibe said the new development will accelerate access to treatment for children and keep them healthy.

According to him, only 24 per cent of children living with HIV have access to antiretroviral drugs.

The UNAIDS chief also said the treatment was heat stable and more palatable than medicines currently available, making it particularly suitable for treating very young children.

"Produced by Indian generic medicines manufacturer, CIPLA, the oral pellets contain an anti-retroviral formulation of lopinavir and ritonavir that can be mixed into a child’s food," he explained.

UNICEF’s Chief of HIV/AIDS section, Craig McClure, said the new formula was a step in the right direction towards saving the lives of more children living with HIV.

"We expect the medication to greatly improve treatment access for more children and support UNICEF’s equity-focused programming aimed at reaching the most disadvantaged children throughout the world,” McClure said in the statement.

HIV infection progresses rapidly in children and, in highly-impacted countries, was a major contributor to child morbidity and mortality.

Without treatment, one in three children who become infected with HIV would die before his or her first birthday and also half would die before their second birthday.

Early initiation of antiretroviral treatment in children substantially reduced the risk of death.

Reports say in spite of global efforts to accelerate access to HIV paediatric care and treatment, fewer than 800,000 of the 3.2 million children living with HIV worldwide had access to antiretroviral medicines in 2013.

dimeji akinloye